LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that CB5300, its new antiviral drug candidate for treatment of Hepatitis C, will be entering into clinical trial assessment following successful in-vitro screening. The screening process was completed in September 2007 at a major contract research institute in Maryland, which resulted in a research report concluding that a family of molecules has been identified as potent inhibitors of flaviviruses.
